It was great to see our team participating in “Accelerating Advanced Therapies: From Innovation to Patient Impact,” hosted by the Advanced Therapy Treatment Centre (ATTC) network.

The event brought together experts from across the cell and gene therapy ecosystem to discuss how we can bridge the gap between scientific innovation and clinical delivery, ultimately improving patient access to transformative therapies.

A few key takeaways from the discussions:

👉 NHS readiness is essential. Developing innovative therapies is only one part of the journey. Ensuring healthcare institutions have the infrastructure, expertise and operational capabilities to deliver them is equally important.
👉 Early collaboration can accelerate clinical trials. Engaging clinicians, industry partners and regulatory stakeholders early can help identify challenges, reduce risks and improve trial delivery.
👉 Market access remains a critical consideration. Beyond clinical development, reimbursement, evidence generation and regulatory pathways play an important role in bringing advanced therapies to patients.
👉 The UK’s global competitiveness continues to evolve. As international competition accelerates, strengthening clinical trial infrastructure, reducing operational barriers, and creating a predictable environment for sponsors will become increasingly important.

A valuable opportunity to learn, connect and reflect on the future of advanced therapies in the UK.